FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to…

FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024 FDA has acknowledged receipt of the resubmission and assigned a PDUFA target action date of June 21, 2024

See original here:
FDA Acceptance of Zevra’s Arimoclomol NDA Filing for Niemann-Pick Disease Type C (NPC) Results in XOMA Making a $1 Million Milestone Payment to...